160 results on '"Philippar, Ulrike"'
Search Results
2. SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation
3. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation
4. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
5. Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML.
6. Identification of isoquinolinone DHODH inhibitor isosteres
7. P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
8. Neuronal Migration in the Murine Rostral Migratory Stream Requires Serum Response Factor
9. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth
10. Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies
11. Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
12. Supplementary Figure from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
13. Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
14. Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
15. Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
16. Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
17. Setdb1 Suppresses Interferon Responses and Nk Cell-Mediated Immunosurveillance Specifically in Monocytic Aml
18. Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma
19. Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
20. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
21. Abstract A28: BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL
22. Macrocyclic Carbon-Linked Pyrazoles As Novel Inhibitors of MCL‑1.
23. BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL
24. Abstract 2133: In pursuit of MCL-1 inhibitors with improved therapeutic window for the treatment of hematological malignancies: Discovery of JNJ-4355
25. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
26. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
27. Abstract 1267: Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas
28. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo
29. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease
30. Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas
31. Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells. (Article)
32. Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
33. Abstract 950: In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models
34. Influence of the bispecific antibody IgG subclass on T cell redirection
35. Simultaneous imaging of GFP, CFP and collagen in tumors in vivo using multiphoton microscopy
36. Abstract 1383: A CRISPR-Cas9 tiling screen to identify functional domains within DNMT1 and/or DNMT3B that can be targeted for therapeutic intervention in AML
37. Abstract LB-303: Substrate-mimetic covalent inhibitor of MALT1 is most effective against CARD11 mutant ABC-DLBCL
38. Discovery of a Novel, First-in-Class Bfl-1 BH3 Mimetic with Pro-Apoptotic Activity
39. Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms
40. SETDB1 Suppresses Interferon Responses and NK Cell-Mediated Immunosurveillance Specifically in Monocytic AML
41. Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML
42. Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma
43. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2Aor NPM1Alterations
44. PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena
45. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
46. PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena
47. PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena
48. A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis
49. Ena/VASP Is Required for Neuritogenesis in the Developing Cortex
50. The SRF Target Gene Fhl2 Antagonizes RhoA/MAL-Dependent Activation of SRF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.